Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Blood (2024) 144 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2024-211472

Published: 2024

Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 10325–10326.

https://doi.org/10.1182/blood-2022-170120

Published: 2022

Journal Articles

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

Josée Golay, Rut Valgardsdottir, Gerta Musaraj, Damiano Giupponi, Orietta Spinelli, Martino Introna

Blood (2019) 133 (13): 1395–1405.

https://doi.org/10.1182/blood-2018-07-864538

Published: 2019

Includes: Supplemental data

Journal Articles

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies

Rut Valgardsdottir, Irene Cattaneo, Christian Klein, Martino Introna, Marina Figliuzzi, Josée Golay

Blood (2017) 129 (19): 2636–2644.

https://doi.org/10.1182/blood-2016-08-735605

Published: 2017

Includes: Multimedia, Supplemental data

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Blood (2016) 128 (22): 1160.

https://doi.org/10.1182/blood.V128.22.1160.1160

Published: 2016

Journal Articles

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Martino Introna, MD, Elisa Gotti, BA, Michela Bonzi, BA, Josee Golay, PhDBA, Alessandra Algarotti, MD, Caterina Micò, MD, Anna Grassi, MD, Cristina Boschini, Maria Luisa Ferrari, BSc, Irene Cavattoni, MD, Ettore Biagi, MD, Adriana Balduzzi, Sr., MD, Attilio Rovelli, MD, Paolo Perseghin, MD, Giuseppe Gaipa, PhD, Andrea Biondi, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3160.

https://doi.org/10.1182/blood.V126.23.3160.3160

Published: 2015

Journal Articles

Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab

Josée Golay, PhD, Fabio Da Roit, BSc, Luca Bologna, BSc, Claudia Ferrara Koller, PhD, Jeanette H. W. Leusen, PhD, Alessandro Rambaldi, MD, Christian Klein, PhD, Martino Introna, MD

Blood (2013) 122 (21): 4419.

https://doi.org/10.1182/blood.V122.21.4419.4419

Published: 2013

Journal Articles

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Josée Golay, PhD, Anna D’amico, PhD, Gianmaria Borleri, Maria Chiara Finazzi, MD, Giulia Quaresmini, MD, Martino Introna, MD, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 3272.

https://doi.org/10.1182/blood.V122.21.3272.3272

Published: 2013

Journal Articles

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Josée Golay, Fabio Da Roit, Luca Bologna, Claudia Ferrara, Jeanette H. Leusen, Alessandro Rambaldi, Christian Klein, Martino Introna

Blood (2013) 122 (20): 3482–3491.

https://doi.org/10.1182/blood-2013-05-504043

Published: 2013

Includes: Supplemental data

Journal Articles

Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

Alice Pievani, Gianmaria Borleri, Daniela Pende, Lorenzo Moretta, Alessandro Rambaldi, Josée Golay, Martino Introna

Blood (2011) 118 (12): 3301–3310.

https://doi.org/10.1182/blood-2011-02-336321

Published: 2011

Includes: Supplemental data

Journal Articles

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies

Alice Pievani, Camilla Belussi, Christian Klein, Alessandro Rambaldi, Josée Golay, Martino Introna

Blood (2011) 117 (2): 510–518.

https://doi.org/10.1182/blood-2010-06-290858

Published: 2011

Journal Articles

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death

Josée Golay, Luca Bologna, Pierre-Alain André, Franz Buchegger, Jean Pierre Mach, Laurence Boumsell, Martino Introna

Blood (2010) 116 (17): 3372–3373.

https://doi.org/10.1182/blood-2010-06-289736

Published: 2010

Journal Articles

Complement in antibody therapy: friend or foe?

Martino Introna, Josée Golay

Blood (2009) 114 (26): 5247–5248.

https://doi.org/10.1182/blood-2009-10-249532

Published: 2009

Journal Articles

Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2 V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.

Ricardo Amaru, MD, Martin Villarroel, MD, Hortencia Miguez, BSc, Rosario Peñaloza, BSc, Gina Torres, BSc, Tiziano Barbui, MD, Josee Golay, PhD, Alessandro Rambaldi, MD

Blood (2009) 114 (22): 1894.

https://doi.org/10.1182/blood.V114.22.1894.1894

Published: 2009

Journal Articles

Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.

Alice Pievani, Gianmaria Borleri, Camilla Belussi, Alessandro Rambaldi, Josee Golay, Martino Introna, MD

Blood (2009) 114 (22): 3024.

https://doi.org/10.1182/blood.V114.22.3024.3024

Published: 2009

Journal Articles

Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays.

Josee Golay, Luca Bologna, Elisa Gotti, Alessandro Rambaldi, Renato Bassan, Martino Introna, MD

Blood (2009) 114 (22): 3445.

https://doi.org/10.1182/blood.V114.22.3445.3445

Published: 2009

Journal Articles

Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease

Martino Introna, Ettore Biagi, Chiara Capelli, Agnese Salvadè, Giovanna D’Amico, Attilio Rovelli, Anna Grassi, Adriana Balduzzi, Josee Golay, Andrea Biondi, Alessandro Rambaldi

Blood (2008) 112 (11): 1171.

https://doi.org/10.1182/blood.V112.11.1171.1171

Published: 2008

Journal Articles

IL-10 Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab.

Josee Golay, PhD, Marzia Leidi, Elisa Gotti, Giuseppe Palumbo, Martino Introna, MD

Blood (2008) 112 (11): 1582.

https://doi.org/10.1182/blood.V112.11.1582.1582

Published: 2008

Journal Articles

Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.

Josee Golay, PhD, Marzia Leidi, BSc, Giuseppe A. Palumbo, MD, Martino Introna, MD

Blood (2006) 108 (11): 2507.

https://doi.org/10.1182/blood.V108.11.2507.2507

Published: 2006

Journal Articles

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Martino Introna, MD, Gianmaria Borleri, Elena Conti, Anna M. Barbui, MD, Raewyn Broady, BSc, Erica Dander, BSc, Giuseppe Gaipa, BSc, Giovanna D’Amico, BSc, Ettore Biagi, MD, Matteo Parma, MD, Enrico Pogliani, MD, Orietta Spinelli, BSc, Donatella Baronciani, MD, Anna Grassi, MD, Josee Golay, PhD, Tiziano Barbui, MD, Andrea Biondi, MD, Alessandro Rambaldi, MD

Blood (2006) 108 (11): 3698.

https://doi.org/10.1182/blood.V108.11.3698.3698

Published: 2006

NARROW

Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death

Complement in antibody therapy: friend or foe?

Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2 V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.

Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.

Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays.

Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease

IL-10 Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab.

Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only